Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study

A better understanding of the long-term safety, efficacy, and immunogenicity of COVID-19 vaccines is needed. This phase 3, randomized, placebo-controlled study for AZD1222 (ChAdOx1 nCoV-19) primary-series vaccination enrolled 32,450 participants in the USA, Chile, and Peru between August 2020 and Ja...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kathryn Shoemaker, Karina Soboleva, Angela Branche, Shivanjali Shankaran, Deborah A. Theodore, Muhammad Bari, Victor Ezeh, Justin Green, Elizabeth Kelly, Dongmei Lan, Urban Olsson, Senthilkumar Saminathan, Nirmal Kumar Shankar, Berta Villegas, Tonya Villafana, Ann R. Falsey, Magdalena E. Sobieszczyk
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2024-08-01
Col·lecció:	Vaccines
Matèries:	AZD1222 (ChAdOx1 nCoV-19) COVID-19 long-term safety SARS-CoV-2 humoral immunogenicity COVID-19 vaccine
Accés en línia:	https://www.mdpi.com/2076-393X/12/8/883
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!